CN102210725A - Application of hypericum japonicum thunb general flavone in preparing medicament for treating hepatic fibrosis - Google Patents

Application of hypericum japonicum thunb general flavone in preparing medicament for treating hepatic fibrosis Download PDF

Info

Publication number
CN102210725A
CN102210725A CN2011101506229A CN201110150622A CN102210725A CN 102210725 A CN102210725 A CN 102210725A CN 2011101506229 A CN2011101506229 A CN 2011101506229A CN 201110150622 A CN201110150622 A CN 201110150622A CN 102210725 A CN102210725 A CN 102210725A
Authority
CN
China
Prior art keywords
herba hyperici
hyperici japonici
total flavones
control group
japonici total
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2011101506229A
Other languages
Chinese (zh)
Other versions
CN102210725B (en
Inventor
苏薇薇
李沛波
王永刚
彭维
杨翠平
吴忠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Yat Sen University
National Sun Yat Sen University
Original Assignee
National Sun Yat Sen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Sun Yat Sen University filed Critical National Sun Yat Sen University
Priority to CN2011101506229A priority Critical patent/CN102210725B/en
Priority to PCT/CN2011/076346 priority patent/WO2012167457A1/en
Publication of CN102210725A publication Critical patent/CN102210725A/en
Application granted granted Critical
Publication of CN102210725B publication Critical patent/CN102210725B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to application of hypericum japonicum thunb general flavone in preparing medicament for treating hepatic fibrosis. The hypericum japonicum thunb general flavone is an effective component extracted from Hypericum japonicum Thunb. The invention further provides a medicinal composition for treating hepatic fibrosis, which comprises the hypericum japonicum thunb general flavone which has effective treatment dosage and serves as an active component, and pharmaceutically acceptable vectors. Animal experiments prove that: the hypericum japonicum thunb has good hepatic fibrosis resistance, has no toxic or side effect, and can be used for preparing the medicament for treating the hepatic fibrosis and for treating clinical hepatic fibrosis.

Description

Herba Hyperici Japonici total flavones is used to prepare the purposes of the medicine for the treatment of hepatic fibrosis
Technical field
The present invention relates to the new purposes of Herba Hyperici Japonici total flavones, especially relate to the new purposes that Herba Hyperici Japonici total flavones is used to prepare the medicine for the treatment of hepatic fibrosis.
Background technology
Hepatic fibrosis be comprise that most of hepatopathy of hepatitis, fatty liver, alcoholic liver etc. develops into liver cirrhosis, hepatocarcinoma must be through link.Studies show that 20%～40% in the patients with liver fibrosis finally develops into liver cirrhosis and even hepatocarcinoma.International hepatopathy academic authority Hans professor Popper proposes " who can stop hepatic fibrosis, and who just can cure most of hepatopathys ", and developing of therefore effective blocking-up hepatic fibrosis is significant to control liver cirrhosis and hepatocarcinoma.Yet, since the complexity of liver cirrhosis pathology mechanism, the present clinical treating liver fibrosis medicine evident in efficacy, that toxic and side effects is little that still lacks.
The existing all types of hepatopaths of China have surpassed 200,000,000 crowd, wherein hepatitis B virus carriers about 9,300 ten thousand, existing disease the infected about 3,000 ten thousand, hepatitis C virus carrier about 4,000 ten thousand, Patients with Fatty Liver is about 1.2 hundred million, and annual newly-increased case surpasses 1,000,000 people, and medical expense reaches more than 1,000 hundred million RMB, cause incomparable heavy financial burden to society, brought huge misery also for countless patients and family.Therefore, seeking the safe drugs with remarkable effect of anti hepatic fibrosis is the focus of current research, also is the critical problem that suits current medical level reality.Chinese medicine has become the focus of domestic and international control hepatic fibrosis research in recent years because of its many target spots effect and the little characteristics of toxic and side effects.
The Chinese medicine Herba Hyperici Japonici is a Guttiferae hypericum Herba Hyperici Japonici Hypericum japonicumThunb. herb.Beginning is stated from " the SHENGCAO property of medicine is wanted fully ", " Zhiwu Mingshi Tukao ", is Guangdong and Guangxi Provinces (Guangdong, Guangxi) genuine medicinal materials.Property is put down, and slightly sweet flavor, little toil are gone into liver, spleen channel.The merit of tool clearing away heat-damp and promoting diuresis, detoxifcation, dissipating blood stasis for subsidence of swelling, cure mainly jaundice due to damp-heat, have loose bowels, dysentery, acute appendicitis, carbuncle furuncle and phyma poison, tonsillitis, aphtha, conjunctival congestion and swelling pain, venom, traumatic injury etc., among the people and clinically be used for the treatment of acute icterohepatitisshock more, evident in efficacy.Changzheng Pharmaceutical Factory, Shanghai was that raw material is made the Herba Hyperici Japonici injection from 1972 with the Herba Hyperici Japonici, was used for the treatment of acute icterohepatitis, and said preparation records in 1977 editions Chinese Pharmacopoeias, and uses till today.
We find in the experimentation in early stage: the Herba Hyperici Japonici total flavones oral administration, the rat liver fibrosis of bile duct caused by ligature, the rat liver fibrosis due to the carbon tetrachloride, the rat liver fibrosis due to the porcine blood serum lumbar injection are had significant therapeutical effect, and do not see toxic and side effects.
Summary of the invention
A kind of new purposes that the purpose of this invention is to provide Herba Hyperici Japonici total flavones is about to the purposes that Herba Hyperici Japonici total flavones is used to prepare the medicine for the treatment of hepatic fibrosis.
The present inventor shows that through number of research projects Herba Hyperici Japonici total flavones can play the effect of treatment hepatic fibrosis, can be used for preparing the medicine for the treatment of hepatic fibrosis.
The total amount that above-mentioned Herba Hyperici Japonici total flavones contains flavone compound is higher than 50%.
According to the further feature of the purposes of Herba Hyperici Japonici total flavones of the present invention, described Herba Hyperici Japonici total flavones be from the Chinese medicine Herba Hyperici Japonici ( Hypericum japonicumThunb.) extract in.
The present invention carries out the zoopery of effect of anti hepatic fibrosis to Herba Hyperici Japonici total flavones.The result shows: the Herba Hyperici Japonici total flavones oral administration has significant therapeutical effect to the rat liver fibrosis of bile duct caused by ligature, the rat liver fibrosis due to the carbon tetrachloride, the rat liver fibrosis due to the porcine blood serum lumbar injection; Can extracellular matrix such as collagen be synthetic by preventing, secretion and promote sedimentary collagen fiber heavily to absorb etc. in the direct intervention liver extracellular matrix metabolism to bring into play its effect of anti hepatic fibrosis, bring into play its effect of anti hepatic fibrosis by works such as antiinflammatories indirectly in order to reduce the hepatic fibrosis risk factor again, thereby produce significantly effect from the generation and the development various aspects of hepatic fibrosis.The prompting Herba Hyperici Japonici total flavones has good effect of anti hepatic fibrosis.
Of the present inventionly experiment showed, that Herba Hyperici Japonici total flavones not only has good effect of anti hepatic fibrosis, and in the rat acute toxicity test, do not show toxic reaction.Zoopery shows: irritate stomach when Herba Hyperici Japonici total flavones with the 4.44g/kg per os and give the SD rat in 14 day observation period, rat does not see death, spirit and behavioral activity are in order, skin is normal by hair cleaning, defecation, body weight gain is normal, food ration is no abnormality seen also, and gross anatomy does not also see that internal organs are unusual.Show that Herba Hyperici Japonici total flavones is safe.
In sum, Herba Hyperici Japonici total flavones has good effect of anti hepatic fibrosis, does not see toxic and side effects, can be used for preparing the medicine for the treatment of hepatic fibrosis, is used for the treatment of clinical hepatic fibrosis.
Description of drawings
Fig. 1 is a hepatic tissue section HE colored graph (* 200), is respectively normal control group, model control group and Herba Hyperici Japonici total flavones group from top to bottom, shows the effect of Herba Hyperici Japonici total flavones to common bile duct caused by ligature rat liver fibrosis.
Fig. 2 is hepatic tissue section α-SMA protein expression immunohistochemical staining figure (* 400), is respectively normal control group, model control group and Herba Hyperici Japonici total flavones group from top to bottom, shows the effect of Herba Hyperici Japonici total flavones to common bile duct caused by ligature rat liver fibrosis.
Fig. 3 is a hepatic tissue section HE colored graph (* 200), is respectively normal control group, model control group and Herba Hyperici Japonici total flavones group from top to bottom, shows that Herba Hyperici Japonici total flavones causes the effect of rat immunity hepatic fibrosis to porcine blood serum.
Fig. 4 is hepatic tissue section α-SMA protein expression immunohistochemical staining figure (* 400), is respectively normal control group, model control group and Herba Hyperici Japonici total flavones group from top to bottom, shows that Herba Hyperici Japonici total flavones causes the effect of rat immunity hepatic fibrosis to porcine blood serum.
Fig. 5 is a hepatic tissue section HE colored graph (* 200), is respectively normal control group, model control group and Herba Hyperici Japonici total flavones group from top to bottom, shows that Herba Hyperici Japonici total flavones is to CCl 4The influence of rat liver fibrosis due to the complex factors.
Fig. 6 is hepatic tissue section α-SMA protein expression immunohistochemical staining figure (* 400), is respectively normal control group, model control group and Herba Hyperici Japonici total flavones group from top to bottom, shows that Herba Hyperici Japonici total flavones is to CCl 4The influence of rat liver fibrosis due to the complex factors.
The specific embodiment
The present invention is described further below in conjunction with embodiment.
Solid among each embodiment in the related solid mixture, the liquid in the liquid, and the solid percentage ratio in the liquid is respectively to calculate with wt/wt, vol/vol, wt/vol, except as otherwise noted.
Embodiment 1: the preparation of Herba Hyperici Japonici total flavones
It is an amount of to get the Herba Hyperici Japonici medical material, and cutting decocts three times with 12 times, 10 times, 8 times water gagings respectively, and each 1 hour, filter, filtrate merges, and is evaporated to contain Herba Hyperici Japonici medical material 0.5g/ml; Join on the preprepared polyamide column, it is light at first to be eluted to eluent color color with distilled water, till adding 60% ethanol elution to hydrochloric acid-magnesium powder reaction again and being negative, collect pure washing liquid, being concentrated into relative density is 1.08～1.10(60 ℃) concentrated solution, in inlet temperature is 100～200 ℃, and leaving air temp is that spray drying promptly gets Herba Hyperici Japonici total flavones under 50～150 ℃ the condition.As stated above, select for use five batches of Herba Hyperici Japonici medical materials to extract altogether, obtain five batches of hypericum japonicum total flavone extractions.
Precision takes by weighing Quercitroside reference substance 10mg, puts in the 50ml measuring bottle, adds dissolve with methanol, is diluted to scale, shakes up, and promptly gets (containing Quercitroside 200 μ g among every 1ml).Precision is measured Quercitroside reference substance solution 0.5ml, 1.0ml, 1.5ml, 2.0ml, 2.5ml, put respectively in the 10ml measuring bottle, respectively add methanol to 2.5ml, add 5% sodium nitrite solution 0.4ml, mixing, placed 6 minutes, add 10% aluminum nitrate solution 0.4ml, shake up, placed 6 minutes, hydro-oxidation sodium test solution 4ml, add water to scale again, shake up, placed 15 minutes, do blank with corresponding reagent, according to ultraviolet visible spectrophotometry (V A of Pharmacopoeia of the People's Republic of China version in 2005), measure absorbance at 500nm wavelength place, be vertical coordinate with the absorbance, concentration is abscissa, the drawing standard curve.Get every crowd of about 50mg of aforementioned Herba Hyperici Japonici total flavones, the accurate title, decide, and puts in the 50ml measuring bottle, and it is an amount of to add methanol, and supersound process (power 360W, frequency 35kHz) 10 minutes adds methanol and is diluted to scale, shakes up, as need testing solution.Precision is measured need testing solution 2ml, puts in the 10ml measuring bottle, adds methanol and is diluted to scale, shakes up, precision is measured 2ml, puts in the 10ml measuring bottle, and the method under the sighting target directrix curve preparation is from " adding methanol to 2.5ml ", measure absorbance in accordance with the law, calculate according to standard curve, promptly.Press dry product and calculate, flavonoid content is with Quercitroside (C in five batches of Herba Hyperici Japonici total flavoness 21H 20O 10) meter, measurement result such as table 1:
Table 1: flavonoid content in five batches of Herba Hyperici Japonici total flavoness
Batch Flavonoid content
1 56.7%
2 60.8%
3 63.5%
4 64.1%
5 66.4%
Choose batches 3 Herba Hyperici Japonici total flavones and carry out the experiment of following examples.
Embodiment 2: Herba Hyperici Japonici total flavones is to the effect of common bile duct caused by ligature rat liver fibrosis
1. laboratory animal:
The SD rat, the SPF level, male and female half and half are provided by Guangdong Medical Lab Animal Center, the animal quality certification number: SCXK(Guangdong) 2008-0002.
Medicine grouping and processing:
Normal control group: distilled water.
Model control group: adopt the common bile duct ligation to cause the rat liver fibrosis model, give the equal-volume distilled water.
The Herba Hyperici Japonici total flavones low dose group: get Herba Hyperici Japonici total flavones (general flavone content is 63.5%) before the experiment, it is 0.9 mg/ml suspension that adding distil water is mixed with concentration.
Dosage group in the Herba Hyperici Japonici total flavones: get Herba Hyperici Japonici total flavones (general flavone content is 63.5%) before the experiment, it is 1.8 mg/ml suspensions that adding distil water is mixed with concentration.
The Herba Hyperici Japonici total flavones high dose group: get Herba Hyperici Japonici total flavones (general flavone content is 63.5%) before the experiment, it is 3.6 mg/ml suspensions that adding distil water is mixed with concentration.
Experimental technique:
Get the SD rat and be divided into 5 groups at random, be i.e. dosage group, Herba Hyperici Japonici total flavones high dose group in normal control group, model control group, Herba Hyperici Japonici total flavones low dose group, the Herba Hyperici Japonici total flavones.It is that 10% chloral hydrate solution is anaesthetized by the dosage lumbar injection concentration of 4ml/kg that rat is respectively organized in modeling, expose bile duct under the liver, ligation liver and bile duct intersection and bile duct and pancreas intersection wipe out the intermediary bile duct in two places to cause complete bile duct obstruction rat model; The processing that do not operate of normal control group.From modeling same day, the basic, normal, high dosage group of Herba Hyperici Japonici total flavones is according to dosage irritated stomach by the 1ml/100g body weight respectively and give Herba Hyperici Japonici total flavones 1 time, continuous 28 days every day.Behind the last administration 1h, each is organized rat and slightly anaesthetizes with ether, and the heart blood sampling is got serum and adopted test kit to detect TBIL, DBIL, ALT, AST, HA, LN, PC-III, TNF-alpha levels; Opening the abdominal cavity then takes out hepatic tissue rapidly and clean the detection of employing test kit SOD, MDA, GSH-Px, Hyp after the homogenate, employing ELISA method detection MMP-1 and the proteic expression of TIMP-1 under normal saline; Other cuts rat liver, and with neutral 10% formalin fixed, wherein lobus sinister carries out HE dyeing, and observing hepatocyte structure and degree of hepatic fibrosis, lobus dexter is used for immunohistochemical method (SABC method) and detects (the expression of α-SMA) of hepatic tissue α-Ji Dongdanbai.
Experimental result:
(1) Herba Hyperici Japonici total flavones is to the influence of liver function index TBIL, DBIL, ALT, AST in the serum
By table 2 as seen, compare with the normal control group, TBIL, DBIL, ALT and AST level all significantly raise (P＜0.01) in the model control group rat blood serum, point out the obstruction of biliary tract of this rat model obvious, and hepatocyte are obviously destroyed.The level of TBIL, DBIL, ALT and AST and model control group compare in the basic, normal, high dosage group of the Herba Hyperici Japonici total flavones rat blood serum, and difference all has statistical significance (P＜0.01 or 0.05), and is dose-effect relationship.Illustrate that Herba Hyperici Japonici total flavones can reduce the jaundice level and the hepatic injury degree of common bile duct caused by ligature hepatic fibrosis rats.
Table 2 Herba Hyperici Japonici total flavones to the influence of liver function index TBIL, DBIL, ALT, AST in the serum (
Figure 104575DEST_PATH_IMAGE001
)
Figure 805946DEST_PATH_IMAGE002
Annotate: compare with the normal control group: ##P＜0.01; Compare with model control group: *P＜0.05 *P＜0.01.
(2) Herba Hyperici Japonici total flavones is to the influence of hepatic fibrosis index PC-III, HA, LN, Hyp
By table 3 as seen, compare with the normal control group, all significantly risings (P＜0.01) of Hyp content in PC-III, HA, LN content and the hepatic tissue are pointed out this rat model to have tangible liver cirrhosis pathology and are changed in the model control group rat blood serum.Hyp content and model control group comparison in PC-III, HA, LN content and the hepatic tissue in the basic, normal, high dosage group of the Herba Hyperici Japonici total flavones rat blood serum, difference all has statistical significance (P＜0.01 or 0.05), and be dose-effect relationship, the prompting Herba Hyperici Japonici total flavones is inhibited to common bile duct caused by ligature rat liver fibrosis.
Table 3 Herba Hyperici Japonici total flavones to the influence of hepatic fibrosis index PC-III, HA, LN, Hyp ( )
Figure 664104DEST_PATH_IMAGE004
Annotate: compare with the normal control group: ##P＜0.01; Compare with model control group: *P＜0.05 *P＜0.01.
(3) Herba Hyperici Japonici total flavones is to the influence of TNF-α in hepatic tissue SOD, GSH-Px, MDA and the serum
By table 4 as seen, compare with the normal control group, model control group liver tissues of rats SOD, GSH-Px are active significantly to reduce (P＜0.01), and MDA content obviously improves (P＜0.01), the antioxidant levels of prompting Liver Fibrosis Model rat liver significantly reduces, and oxidative damage is obvious.In addition, can participate in the also significantly rising (P＜0.01) of important cytokine TNF-α of liver fibrosis process regulation and control by number of mechanisms.And TNF-α and model control group comparison in the basic, normal, high dosage group of Herba Hyperici Japonici total flavones liver tissues of rats SOD, GSH-Px, MDA and the serum, difference all has statistical significance (P＜0.01 or 0.05), and is dose-effect relationship.Illustrate that Herba Hyperici Japonici total flavones can improve the oxidation resistance of Liver Fibrosis Model rat liver, significantly reduce the oxidative damage of liver, also can suppress the secretion of TNF-α, thereby suppress the development of hepatic fibrosis.
Table 4 Herba Hyperici Japonici total flavones to the influence of TNF-α in hepatic tissue SOD, GSH-Px, MDA and the serum (
Figure 434350DEST_PATH_IMAGE003
)
Annotate: compare with the normal control group: ##P＜0.01; Compare with model control group: *P＜0.05 *P＜0.01.
(4) Herba Hyperici Japonici total flavones is to the influence of hepatic tissue MMP-1 and TIMP-1 protein expression
By table 5 as seen, compare with the normal control group, model control group liver tissues of rats TIMP-1 protein expression significantly increases (P＜0.01), and hepatic tissue MMP-1 does not have significant change (P＞0.05), the TIMP-1 protein expression of prompting Liver Fibrosis Model rat liver increases, and extracellular matrix decomposes minimizing in the liver.And the basic, normal, high dosage group of Herba Hyperici Japonici total flavones liver tissues of rats TIMP-1 protein expression and model control group are relatively, and difference all has statistical significance (P＜0.01 or 0.05), and is dose-effect relationship.Illustrate that Herba Hyperici Japonici total flavones can suppress the TIMP-1 protein expression of Liver Fibrosis Model rat liver, significantly promotes the decomposition of extracellular matrix in the liver.
Table 5 Herba Hyperici Japonici total flavones to the influence of hepatic tissue MMP-1 and TIMP-1 protein expression (
Figure 919000DEST_PATH_IMAGE003
)
Figure 404952DEST_PATH_IMAGE006
Annotate: compare with the normal control group: ##P＜0.01; Compare with model control group: *P＜0.05 *P＜0.01.
(5) Herba Hyperici Japonici total flavones is to the influence of hepatic tissue pathology variation
Hepatic tissue HE coloration result is seen Fig. 1.The result shows: normal control group lobules of liver clear in structure, and hepatocyte is normal substantially, and the portal area clear in structure is not seen little bile duct and the obvious hypertrophy of fibrous tissue around the portal area reaches; Model control group sees that the lobules of liver structure is unintelligible, the hepatocyte edema is obvious in the lobule, focal hepatic necrosis is more, the remarkable hypertrophy of little bile duct, and being that the center is radial with the portal area extends in liver parenchyma, outgrowth bile duct is the garland sample, and the hypertrophy bile duct is on every side with obvious proliferation of fibrous tissue and cell infiltration; In the dosage Herba Hyperici Japonici total flavones organize visible lobules of liver clear in structure, little bile duct is slightly hypertrophy only of center with the portal area, accompanies slight proliferation of fibrous tissue around the hypertrophy bile duct.
(6) Herba Hyperici Japonici total flavones is to the influence of hepatic tissue α-SMA protein expression
Hepatic tissue α-SMA protein expression immunohistochemical staining the results are shown in Figure 2.The result shows: liver tissues of rats α-SMA protein expression is colored as pale brown color based on cell cytoplasm, mainly is distributed in the portal area.The only visible a small amount of positive expression of hepatic tissue portal area α-SMA of normal control group; Visible α-the SMA of model control group area of positive expression in hepatic tissue significantly increases; The area of middle dosage Herba Hyperici Japonici total flavones group α-SMA positive expression in hepatic tissue obviously is less than model control group, is tending towards normal.
Embodiment 3: Herba Hyperici Japonici total flavones causes the effect of rat immunity hepatic fibrosis to porcine blood serum
1. laboratory animal:
The SD rat, the SPF level, male and female half and half are provided by Guangdong Medical Lab Animal Center, the animal quality certification number: SCXK(Guangdong) 2008-0002.
, medicine grouping with handle:
Normal control group: distilled water.
Model control group: adopt porcine blood serum to cause the rat immunity Liver Fibrosis Model, give the equal-volume distilled water.
The Herba Hyperici Japonici total flavones low dose group: get Herba Hyperici Japonici total flavones (general flavone content is 63.5%) before the experiment, it is 0.9 mg/ml suspension that adding distil water is mixed with concentration.
Dosage group in the Herba Hyperici Japonici total flavones: get Herba Hyperici Japonici total flavones (general flavone content is 63.5%) before the experiment, it is 1.8 mg/ml suspensions that adding distil water is mixed with concentration.
The Herba Hyperici Japonici total flavones high dose group: get Herba Hyperici Japonici total flavones (general flavone content is 63.5%) before the experiment, it is 3.6 mg/ml suspensions that adding distil water is mixed with concentration.
Experimental technique:
Get the SD rat and be divided into 5 groups at random, be i.e. dosage group, Herba Hyperici Japonici total flavones high dose group in normal control group, model control group, Herba Hyperici Japonici total flavones low dose group, the Herba Hyperici Japonici total flavones.All the other respectively organize the rats by intraperitoneal injection porcine blood serum except that the normal control group, every injection 0.5 ml, 2 times weekly, the time be Tuesday, the mornings 8 Saturday point, the modeling time was 12 weeks.The normal control group is pressed the same manner injecting normal saline.From modeling same day, the basic, normal, high dosage group of Herba Hyperici Japonici total flavones is according to dosage irritated stomach respectively and give Herba Hyperici Japonici total flavones 1 time, continuous 12 weeks every day; Normal control group and model control group gavage the equal-volume distilled water.Behind the last administration 1h, each is organized rat and slightly anaesthetizes with ether, in the ventral aorta blood sampling, gets serum and adopts test kit to detect ALT, AST, ALB, TP, HA, LN, PC-III level; Open the abdominal cavity then and take out hepatic tissue rapidly, in normal saline, clean, adopt test kit to detect Hyp after the homogenate, adopt the ELISA method to detect MMP-1 and the proteic expression of TIMP-1; Other cuts rat liver, and with neutral 10% formalin fixed, wherein lobus sinister carries out HE dyeing, and observing hepatocyte structure and degree of hepatic fibrosis, lobus dexter is used for immunohistochemical method (SABC method) and detects (the expression of α-SMA) of hepatic tissue α-Ji Dongdanbai.
Experimental result:
(1) Herba Hyperici Japonici total flavones is to the influence of liver function index ALT, AST, ALB/GLB in the serum
By table 6 as seen, compare with the normal control group, ALT, AST level significantly raise (P＜0.01) in the model control group rat blood serum, and the ALB/GLB value significantly reduces (P＜0.01), points out the hepatocyte of this rat model obviously to damage, and liver function significantly changes.The level of ALT, AST and ALB/GLB value and model control group compare in the basic, normal, high dosage group of the Herba Hyperici Japonici total flavones rat blood serum, and difference all has statistical significance (P＜0.01 or 0.05), and is dose-effect relationship.Illustrate that Herba Hyperici Japonici total flavones can reduce the hepatic injury degree of hepatic fibrosis rats due to the lumbar injection porcine blood serum.
Table 6 Herba Hyperici Japonici total flavones to the influence of liver function index ALT, AST, ALB/GLB in the serum (
Figure 881851DEST_PATH_IMAGE003
)
Figure 620131DEST_PATH_IMAGE007
Annotate: compare with the normal control group: ##P＜0.01; Compare with model control group: *P＜0.05 *P＜0.01.
(2) Herba Hyperici Japonici total flavones is to the influence of hepatic fibrosis index PC-III, HA, LN, Hyp
By table 7 as seen, compare with the normal control group, all significantly risings (P＜0.01) of Hyp content in PC-III, HA, LN content and the hepatic tissue are pointed out this rat model to have tangible liver cirrhosis pathology and are changed in the model control group rat blood serum.Hyp content and model control group comparison in PC-III, HA, LN content and the hepatic tissue in the basic, normal, high dosage group of the Herba Hyperici Japonici total flavones rat blood serum, difference all has statistical significance (P＜0.01 or 0.05), and be dose-effect relationship, the prompting Herba Hyperici Japonici total flavones is inhibited to rat immunity hepatic fibrosis due to the lumbar injection porcine blood serum.
Table 7 Herba Hyperici Japonici total flavones to the influence of hepatic fibrosis index PC-III, HA, LN, Hyp (
Figure 923067DEST_PATH_IMAGE003
)
Figure 794684DEST_PATH_IMAGE008
Annotate: compare with the normal control group: ##P＜0.01; Compare with model control group: *P＜0.05, *P＜0.01.
(3) Herba Hyperici Japonici total flavones is to hepatic tissue MMP-1 and the proteic influence of TIMP-1
By table 8 as seen, compare with the normal control group, model control group liver tissues of rats TIMP-1 protein expression significantly increases (P＜0.01), and hepatic tissue MMP-1 does not have significant change (P＞0.05), the TIMP-1 protein expression of prompting Liver Fibrosis Model rat liver increases, and extracellular matrix decomposes minimizing in the liver.And the basic, normal, high dosage group of Herba Hyperici Japonici total flavones liver tissues of rats TIMP-1 protein expression and model control group are relatively, difference all has statistical significance (P＜0.01 or 0.05), and be dose-effect relationship, illustrate that Herba Hyperici Japonici total flavones can suppress the TIMP-1 protein expression of immunological liver fibrosis rat model liver due to the lumbar injection porcine blood serum, significantly promotes the decomposition of extracellular matrix in the liver.
Table 8 Herba Hyperici Japonici total flavones to the influence of hepatic tissue MMP-1 and TIMP-1 protein expression (
Figure 892084DEST_PATH_IMAGE003
)
Figure 117660DEST_PATH_IMAGE009
Annotate: compare with the normal control group: ##P＜0.01; Compare with model control group: *P＜0.05 *P＜0.01.
(4) Herba Hyperici Japonici total flavones is to the influence of hepatic tissue pathology variation
Hepatic tissue HE coloration result is seen Fig. 3.The result shows: hepatocyte is normal in the normal control group lobules of liver clear in structure, lobule, and the portal area clear in structure is not seen little bile duct and proliferation of fibrous tissue around portal area and the portal area; Model control group is seen the lobules of liver structural fuzzy, hepatocyte edema in the lobule, focal hepatic necrosis, the a large amount of hypertrophy of little bile duct, being that the center is radial with the portal area extends in liver parenchyma, and outgrowth bile duct is the garland sample, accompanies proliferation of fibrous tissue and cell infiltration around the hypertrophy bile duct; It is more clear that middle dosage Herba Hyperici Japonici total flavones is organized visible lobules of liver structure, and little bile duct is the slight hypertrophy in center with the portal area, accompanies slight proliferation of fibrous tissue around the hypertrophy bile duct.
(5) Herba Hyperici Japonici total flavones is to the influence of hepatic tissue α-SMA protein expression
Hepatic tissue α-SMA protein expression immunohistochemical staining the results are shown in Figure 2.The result shows: liver tissues of rats α-SMA protein expression is colored as pale brown color based on cell cytoplasm, mainly is distributed in the portal area.Visible α-the SMA of normal control group is at a small amount of positive expression in hepatic tissue portal area; Visible α-the SMA of model control group area of positive expression in hepatic tissue increases greatly; The area of middle dosage Herba Hyperici Japonici total flavones group α-SMA positive expression in hepatic tissue obviously is less than model control group, is tending towards normal.
Embodiment 4: Herba Hyperici Japonici total flavones is to CCl 4The influence of rat liver fibrosis due to the complex factors
1, laboratory animal:
The SD rat, the SPF level, male and female half and half are provided by Guangdong Medical Lab Animal Center, the animal quality certification number: SCXK(Guangdong) 2008-0002.
, medicine grouping with handle:
Normal control group: distilled water.
Model control group: adopt CCl 4Complex factors cause the rat liver fibrosis model, give the equal-volume distilled water.
The Herba Hyperici Japonici total flavones low dose group: get Herba Hyperici Japonici total flavones (general flavone content is 63.5%) before the experiment, it is 0.9 mg/ml suspension that adding distil water is mixed with concentration.
Dosage group in the Herba Hyperici Japonici total flavones: get Herba Hyperici Japonici total flavones (general flavone content is 63.5%) before the experiment, it is 1.8 mg/ml suspensions that adding distil water is mixed with concentration.
The Herba Hyperici Japonici total flavones high dose group: get Herba Hyperici Japonici total flavones (general flavone content is 63.5%) before the experiment, it is 3.6 mg/ml suspensions that adding distil water is mixed with concentration.
, experimental technique:
Get the SD rat, except that 10 of normal control groups, all the other the 1st weeks of rat (first) are used pure CCl 45 ml/kg are to the rat back subcutaneous injection, and the 2nd～6 week was used 40% CCl 4-olive oil 3 ml/kg are to the rat back subcutaneous injection, 2 times/week.In the 1st～6 week simultaneously, and with the unique drinking-water of 20% ethanol as rat.In continuous 6 weeks, duplicate the rat liver fibrosis model.To duplicate CCl 4Liver Fibrosis Model to the 6 week and the rat of survival is divided into 4 groups at random by sex and body weight, 10 every group, add the normal control group, amount to 5 groups.Give medicine or distilled water then respectively: the basic, normal, high dosage group of Herba Hyperici Japonici total flavones is according to dosage irritated stomach respectively and give Herba Hyperici Japonici total flavones 1 time, continuous 12 weeks every day; Normal control group and model control group gavage the equal-volume distilled water.Behind the last administration 1h, each is organized rat and slightly anaesthetizes with ether, in the ventral aorta blood sampling, gets serum and adopts test kit to detect TBIL, DBIL, ALT, AST, HA, LN, PC-III, TNF-alpha levels; Opening the abdominal cavity then takes out hepatic tissue rapidly and clean the detection of employing test kit SOD, MDA, GSH-Px, Hyp after the homogenate, employing ELISA method detection MMP-1 and the proteic expression of TIMP-1 under normal saline; Other cuts rat liver, and with neutral 10% formalin fixed, wherein lobus sinister carries out HE dyeing, and observing hepatocyte structure and degree of hepatic fibrosis, lobus dexter is used for immunohistochemical method (SABC method) and detects (the expression of α-SMA) of hepatic tissue α-Ji Dongdanbai.
, experimental result:
(1) Herba Hyperici Japonici total flavones is to the influence of liver function index TBIL, DBIL, ALT, AST in the serum
By table 9 as seen, compare with the normal control group, TBIL, DBIL, ALT and AST level all significantly raise (P＜0.01) in the model control group rat blood serum, point out the obstruction of biliary tract of this rat model obvious, and hepatocyte are obviously destroyed.The level of TBIL, DBIL, ALT and AST and model control group are relatively in the basic, normal, high dosage group of the Herba Hyperici Japonici total flavones rat blood serum, difference all has statistical significance (P＜0.01 or 0.05), and be dose-effect relationship, illustrate that Herba Hyperici Japonici total flavones can reduce the jaundice level and the hepatic injury degree of common bile duct caused by ligature hepatic fibrosis rats.
Table 9 Herba Hyperici Japonici total flavones to the influence of liver function index TBIL, DBIL, ALT, AST in the serum (
Figure 949919DEST_PATH_IMAGE003
)
Figure 944551DEST_PATH_IMAGE010
Annotate: compare with the normal control group: ##P＜0.01; Compare with model control group: *P＜0.05 *P＜0.01.
(2) Herba Hyperici Japonici total flavones is to the influence of hepatic fibrosis index PC-III, HA, LN, Hyp
By table 10 as seen, compare with the normal control group, all significantly risings (P＜0.01) of Hyp content in PC-III, HA, LN content and the hepatic tissue are pointed out this rat model to have tangible liver cirrhosis pathology and are changed in the model control group rat blood serum.Hyp content and model control group comparison in PC-III, HA, LN content and the hepatic tissue in the basic, normal, high dosage group of the Herba Hyperici Japonici total flavones rat blood serum, difference all has statistical significance (P＜0.01 or 0.05), and be dose-effect relationship, the prompting Herba Hyperici Japonici total flavones is to CCl 4Complex factors cause rat liver fibrosis inhibited.
Table 10 Herba Hyperici Japonici total flavones to the influence of hepatic fibrosis index PC-III, HA, LN, Hyp (
Figure 944343DEST_PATH_IMAGE003
)
Figure 657216DEST_PATH_IMAGE011
Annotate: compare with the normal control group: ##P＜0.01; Compare with model control group: *P＜0.05 *P＜0.01.
(3) Herba Hyperici Japonici total flavones is to the influence of TNF-α in hepatic tissue SOD, GSH-Px, MDA and the serum
By table 11 as seen, compare with the normal control group, model control group liver tissues of rats SOD, GSH-Px are active significantly to reduce (P＜0.01), and MDA content obviously improves (P＜0.01), the antioxidant levels of prompting Liver Fibrosis Model rat liver significantly reduces, and oxidative damage is obvious.In addition, can participate in the also significantly rising (P＜0.01) of important cytokine TNF-α of liver fibrosis process regulation and control by number of mechanisms.And TNF-α and model control group comparison in the basic, normal, high dosage group of Herba Hyperici Japonici total flavones liver tissues of rats SOD, GSH-Px, MDA and the serum, difference all has statistical significance (P＜0.01 or 0.05), and be dose-effect relationship, illustrate that Herba Hyperici Japonici total flavones can improve CCl 4The oxidation resistance of the Liver Fibrosis Model rat liver that complex factors cause significantly reduces the oxidative damage of liver, also can suppress the secretion of TNF-α.
Table 11 Herba Hyperici Japonici total flavones to the influence of TNF-α in hepatic tissue SOD, GSH-Px, MDA and the serum (
Figure 36376DEST_PATH_IMAGE003
)
Figure 154023DEST_PATH_IMAGE012
Annotate: compare with the normal control group: ##P＜0.01; Compare with model control group: *P＜0.05 *P＜0.01.
(4) Herba Hyperici Japonici total flavones is to the influence of hepatic tissue MMP-1 and TIMP-1 protein expression
By table 12 as seen, compare with the normal control group, model control group liver tissues of rats TIMP-1 protein expression significantly increases (P＜0.01), and hepatic tissue MMP-1 does not have significant change (P＞0.05), the TIMP-1 protein expression of prompting Liver Fibrosis Model rat liver increases, and extracellular matrix decomposes minimizing in the liver.And the basic, normal, high dosage group of Herba Hyperici Japonici total flavones liver tissues of rats TIMP-1 protein expression and model control group are relatively, and difference all has statistical significance (P＜0.01 or 0.05), and is dose-effect relationship, illustrates that Herba Hyperici Japonici total flavones can suppress CCl 4Complex factors cause the TIMP-1 protein expression of Liver Fibrosis Model rat liver, significantly promote the decomposition of extracellular matrix in the liver.
Table 12 Herba Hyperici Japonici total flavones to the influence of hepatic tissue MMP-1 and TIMP-1 protein expression (
Figure 327646DEST_PATH_IMAGE003
)
Figure 462568DEST_PATH_IMAGE013
Annotate: compare with the normal control group: ##P＜0.01; Compare with model control group: *P＜0.05 *P＜0.01.
(5) Herba Hyperici Japonici total flavones is to the influence of hepatic tissue pathology variation
Hepatic tissue HE coloration result is seen Fig. 5.The result shows: normal control group lobules of liver clear in structure, and hepatocyte is normal in the lobule, portal area clear in structure, portal area and do not see little bile duct and proliferation of fibrous tissue on every side; Model control group is seen the lobules of liver structural fuzzy, hepatocyte edema in the lobule, and focal necrosis, a large amount of hypertrophy of little bile duct are that the center is radial with the portal area extends in liver parenchyma, and outgrowth bile duct is obvious, and on every side with proliferation of fibrous tissue and cell infiltration; It is more clear that middle dosage Herba Hyperici Japonici total flavones is organized visible lobules of liver structure, and little bile duct is the slight hypertrophy in center with the portal area, accompanies slight proliferation of fibrous tissue around the hypertrophy bile duct.
(6) Herba Hyperici Japonici total flavones is to the influence of hepatic tissue α-SMA protein expression
Hepatic tissue α-SMA protein expression immunohistochemical staining the results are shown in Figure 6.The result shows: liver tissues of rats α-SMA protein expression is colored as sundown based on cell cytoplasm, mainly is distributed in the portal area.Visible α-the SMA of normal control group has a small amount of positive expression in the hepatic tissue portal area; Visible α-the SMA of model control group area of positive expression in hepatic tissue increases greatly; The area of middle dosage Herba Hyperici Japonici total flavones group α-SMA positive expression in hepatic tissue obviously is less than model control group, is tending towards normal.
Embodiment 5:SD rat oral gives the Herba Hyperici Japonici total flavones acute toxicity test
1, laboratory animal:
24 of SPF level SD rats, male and female half and half, body weight 130～150g, west, Shanghai pul must provide (production licence number: SCXK(Shanghai)-2003-0002) by triumphant laboratory animal company limited.
, experimental technique:
EXPERIMENTAL DESIGN administration group and blank group, every group of 12 animals, male and female half and half.Administration group dosage is 4.44g/kg, by Cmax 222mg/ml, the administration volume 20ml/kg gastric infusion that can pass through to irritate the stomach pin.Matched group is irritated stomach and is given the equal-volume sterilized water for injection.
The outward appearance of observation every day and record rat, the mental status, breathing, skin are by ordinary circumstance and other poisoning manifestations and death condition such as hair, fecaluria, eye, ear, nose, oral cavity, genitals.Measured rat body weight once in per two days, and measured the rat food ration weekly once, observed continuously 14 days.
, experimental result:
(1) general situation and death condition are observed
Until the 14th day, each animal spirit and behavioral activity were in order, skin is normal by hair cleaning, defecation, also do not see other toxic reaction symptoms after the administration.Observe end back gross anatomy and do not see that internal organs are obviously unusual.
(2) body weight
Female, great and mighty or powerful Mus is compared in female, the great and mighty or powerful Mus body weight of each time point body weight and sterilized water for injection matched group, and the difference not statistically significant (P〉0.05), think that Herba Hyperici Japonici total flavones per os gastric infusion does not have obvious influence to rat body weight.See table 13 for details.
Table 13 Herba Hyperici Japonici total flavones single oral gastric infusion to the influence of SD rat body weight (
Figure 583102DEST_PATH_IMAGE003
)
Figure 286747DEST_PATH_IMAGE014
In the last table, " matched group " is meant " blank group ", and " administration group " is meant " Herba Hyperici Japonici total flavones administration group ".
(3) food ration
Herba Hyperici Japonici total flavones per os gastric infusion does not have obvious influence to the average food ration of female, male Mus.See table 14 for details.
Table 14 Herba Hyperici Japonici total flavones single oral gastric infusion is to the influence of the average food ration of SD rat.
, conclusion:
In sum, under this laboratory condition, the SD rat is with Cmax 222mg/ml, maximum volume 20ml/kg single oral is irritated the Herba Hyperici Japonici total flavones of stomach 4.44g/kg, in 14 day observation period, death does not appear in rat, and spirit and behavioral activity are in order, skin is normal by hair cleaning, defecation, body weight gain is normal, the food ration no abnormality seen.Observe end back gross anatomy and do not see that internal organs are unusual.

Claims (3)

1. Herba Hyperici Japonici total flavones is used to prepare the purposes of the medicine for the treatment of hepatic fibrosis.
2. purposes according to claim 1 is characterized in that: in the described Herba Hyperici Japonici total flavones, the total content of flavone compound is higher than 50%.
3. purposes according to claim 1 is characterized in that: described Herba Hyperici Japonici total flavones be from the Chinese medicine Herba Hyperici Japonici ( Hypericum japonicumThunb.) extract in.
CN2011101506229A 2011-06-07 2011-06-07 Application of hypericum japonicum thunb general flavone in preparing medicament for treating hepatic fibrosis Active CN102210725B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN2011101506229A CN102210725B (en) 2011-06-07 2011-06-07 Application of hypericum japonicum thunb general flavone in preparing medicament for treating hepatic fibrosis
PCT/CN2011/076346 WO2012167457A1 (en) 2011-06-07 2011-06-24 Use of hypericum japonicum thunb. general flavone in preparing medicament for treating hepatic fibrosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2011101506229A CN102210725B (en) 2011-06-07 2011-06-07 Application of hypericum japonicum thunb general flavone in preparing medicament for treating hepatic fibrosis

Publications (2)

Publication Number Publication Date
CN102210725A true CN102210725A (en) 2011-10-12
CN102210725B CN102210725B (en) 2013-08-21

Family

ID=44742410

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011101506229A Active CN102210725B (en) 2011-06-07 2011-06-07 Application of hypericum japonicum thunb general flavone in preparing medicament for treating hepatic fibrosis

Country Status (2)

Country Link
CN (1) CN102210725B (en)
WO (1) WO2012167457A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108037234B (en) * 2017-12-05 2020-02-07 广东沙溪制药有限公司 Quality detection method of abrus herb hepatitis granules

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1660307A (en) * 2004-12-29 2005-08-31 中国人民解放军第二军医大学 Combination of Chinese traditional medicine for treating disease of liver and preparation method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1660307A (en) * 2004-12-29 2005-08-31 中国人民解放军第二军医大学 Combination of Chinese traditional medicine for treating disease of liver and preparation method

Also Published As

Publication number Publication date
WO2012167457A1 (en) 2012-12-13
CN102210725B (en) 2013-08-21

Similar Documents

Publication Publication Date Title
CN101357219B (en) Medicine for treating chronic hepatitis B
CN101293016B (en) Application of cistanche salsa extract in preparing medicament for treating parkinsonism
CN101856418B (en) Pharmaceutical preparation for preventing nephritis and preparation method thereof
CN103041247B (en) Traditional Chinese medicine suppository for curing colpitis and preparation method thereof
KR20000061327A (en) Natural pharmaceutical composition for prevention and treatment of hepatic disease.
CN109512870B (en) Pharmaceutical composition, preparation method and application thereof
CN107334798A (en) Set conopsea extraction and preparation method and the application in rheumatoid arthritis medicine is treated
CN102210725B (en) Application of hypericum japonicum thunb general flavone in preparing medicament for treating hepatic fibrosis
CN103142774B (en) Application of total saponin extract of lobedfruit schizocapsarhizome in treatment of liver cancer and nasopharyngeal carcinoma
CN105012826A (en) Alpinia oxyphylla leaf extract and preparation method and application thereof
CN103830288B (en) Match certain herbaceous plants with big flowers extractive of general flavone and its production and use
CN101524411B (en) High-capacity Kuhuang injection and preparation method thereof
CN102836152B (en) Application of physalin B in preparation of medicine for curing and/or preventing schistosomiasis
CN101138581B (en) Traditional chinese medicine preparation for treating urinary system infection contamination and method of preparing the same
CN106309758A (en) Pharmaceutical composition with efficacy of resisting gastrointestinal cancer
CN104491101B (en) Preparing method of traditional Chinese medicine preparation for treatment of chronic renal failure
CN103933386B (en) Compound hemophiliac capsule used for treating hemophilia and preparation method thereof
CN103816392B (en) Pharmaceutical composition of a kind for the treatment of organs fibrosis and its production and use
CN105521327B (en) Medicinal composition for preventing and/or curinng alcoholic liver disease or liver cancer
CN105434895A (en) Gastrodia elata rhodiola rosea cream and preparation method thereof
CN107050359A (en) Treat strong medicine preparation of chronic pelvic inflammatory disease sequelae and preparation method thereof
CN104491102B (en) Colon positioning traditional Chinese medicine preparation for treating chronic kidney failure
CN108498655A (en) It is a kind of to be used for clearing heat and detoxicating blue gold oral solution and preparation method thereof
CN104587017B (en) A kind of Clearing heat and removing obstruction of fu-organs, pharmaceutical composition of the promoting flow of qi and blood circulation and its production and use
CN101766675A (en) Preparation method of silktree albizia bark extract for inhibiting angiogenesis and application

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent for invention or patent application
CB03 Change of inventor or designer information

Inventor after: Li Peibo

Inventor after: Su Weiwei

Inventor after: Wang Yonggang

Inventor after: Peng Wei

Inventor after: Yang Cuiping

Inventor after: Wu Zhong

Inventor before: Su Weiwei

Inventor before: Li Peibo

Inventor before: Wang Yonggang

Inventor before: Peng Wei

Inventor before: Yang Cuiping

Inventor before: Wu Zhong

COR Change of bibliographic data

Free format text: CORRECT: INVENTOR; FROM: SU WEIWEI LI PEIBO WANG YONGGANG PENG WEI YANG CUIPING WU ZHONG TO: LI PEIBO SU WEIWEI WANG YONGGANG PENG WEI YANG CUIPING WU ZHONG

C14 Grant of patent or utility model
GR01 Patent grant